Sjögren's disease & overlap diseases
Cancer risk in Sjögren’s disease: A longitudinal cohort study on incidence, predictors, and mortality impact
Authors' conclusion
Patients with SjD have an elevated malignancy risk, mainly driven by NHL, while solid tumor risk remains modest. Malignancy was a significant contributor to mortality.
Study context
- Population
- Patients with Sjögren's disease (SjD) fulfilling 2002 American-European Consensus Group criteria; median follow-up 9.5 yearsmedian follow-up 9.5 years
- Participants
- 314 patients
- Exposure
- SjD patients vs the general population
- SjDn = 314
- Outcome
- SIRs of overall malignancies, hematologic malignancies and solid tumors vs the general population
Methodological detailsmulticentre, multivariate Cox regression, standardized incidence ratios (SIRs) vs general population (GLOBOCAN)
- Multicentre
- Multivariate Cox regression
- SIRs vs general population (GLOBOCAN)
Main finding
As reported in the abstract
Cancer risk vs general population (SIR) · median follow-up 9.5 years
Total malignancies identified
22
7.01%
Overall cancer SIR
1.68 (1.68-1.69) (95% CI)
Hematologic malignancies SIR
3.55 (3.54-3.56) (95% CI)
Solid tumors SIR
1.54 (1.53-1.55) (95% CI)
Observational data: associations, not effects.
Further findings
Independent predictors of malignancy
- Older age, smoking, lymphadenopathy, splenomegaly and cryoglobulinemia
- Multivariate Cox regression
Cancer-related mortality
- Proportion of deaths due to cancer
- 23.8%
- RR of death
- 2.21
- EFE
- 55%
Original publication
Cancer risk in Sjögren’s disease: A longitudinal cohort study on incidence, predictors, and mortality impact. Semin Arthritis Rheum. Published 4 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →